Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) Invested Capital (2023 - 2025)

Beta Bionics' Invested Capital history spans 3 years, with the latest figure at $287.6 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 217.22% year-over-year to $287.6 million; the TTM value through Dec 2025 reached $287.6 million, up 217.22%, while the annual FY2025 figure was $287.6 million, 217.22% up from the prior year.
  • Invested Capital for Q4 2025 was $287.6 million at Beta Bionics, down from $294.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $313.8 million in Q1 2025 and bottomed at -$245.4 million in Q4 2024.
  • The 3-year median for Invested Capital is -$203.1 million (2023), against an average of $9.4 million.
  • The largest annual shift saw Invested Capital decreased 20.8% in 2024 before it surged 246.39% in 2025.
  • A 3-year view of Invested Capital shows it stood at -$203.1 million in 2023, then dropped by 20.8% to -$245.4 million in 2024, then soared by 217.22% to $287.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Invested Capital are $287.6 million (Q4 2025), $294.8 million (Q3 2025), and $301.6 million (Q2 2025).